Literature DB >> 9248959

Susceptibility testing of fungi and correlation with clinical outcome.

M A Ghannoum1.   

Abstract

With recent developments in the field of mycology such as increased incidence of fungal infections, the introduction of newer, safer antifungals, and the emergence of resistance, the need for clinically relevant antifungal susceptibility testing methods is obvious. Studies performed over the past decade have allowed the NCCLS Subcommittee on Antifungal Testing to achieve consensus on a new standardized broth dilution method for in vitro susceptibility testing of yeast (NCCLS M27). This review summarizes the studies correlating in vitro susceptibility testing and clinical outcome, presents tentative breakpoints for fluconazole and itraconazole, and emphasizes the utility of in vitro testing in the management of patients with candidiasis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9248959

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  10 in total

1.  Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  T J Walsh; C E Gonzalez; S Piscitelli; J D Bacher; J Peter; R Torres; D Shetti; V Katsov; K Kligys; C A Lyman
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

Review 2.  Candida biofilms: an update.

Authors:  Gordon Ramage; Stephen P Saville; Derek P Thomas; José L López-Ribot
Journal:  Eukaryot Cell       Date:  2005-04

3.  Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.

Authors:  Bettina C Fries; Emily Cook; Xiabo Wang; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Analysis of growth characteristics of filamentous fungi in different nutrient media.

Authors:  J Meletiadis; J F Meis; J W Mouton; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

5.  Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates.

Authors:  C J Jessup; J Warner; N Isham; I Hasan; M A Ghannoum
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 6.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

7.  In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies.

Authors:  Gordon Ramage; Kacy VandeWalle; Stefano P Bachmann; Brian L Wickes; José L López-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

8.  Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms.

Authors:  G Ramage; K Vande Walle; B L Wickes; J L López-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

9.  Relationship between susceptibility of Candida spp. isolates to amphotericin B and death or survival of patients with candidemia episodes.

Authors:  Sydney Hartz Alves; Everton Boff; Patricia Pozzatti; Liliane A Scheid; Erico de Loreto; Loiva T Ottoneli Oliveira; Valério Aquino; Luiz Carlos Severo; Janio Morais Santurio
Journal:  Mycopathologia       Date:  2008-09-26       Impact factor: 2.574

10.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.